Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cabozantinib + lutetium Lu 177 dotatate
- Development stage
- Unknown
- Lead developer
- St. Joseph Health
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
cabozantinib + lutetium Lu 177 dotatate is a combination therapy being evaluated for the treatment of somatostatin receptor 2 (SSTR2) positive neuroendocrine tumors (NETs). It consists of cabozantinib, a small molecule multi-kinase inhibitor that targets MET, VEGFR2, and AXL to inhibit tumor growth and angiogenesis, and lutetium Lu 177 dotatate, a radiolabeled somatostatin analog. Lutetium Lu 177 dotatate binds to SSTR2 on tumor cells, delivering targeted beta-minus radiation that induces DNA damage and cell death. The combination is currently being studied by Providence Health & Services in a Phase Ib trial (NCT05360238) to determine the safety and maximum tolerated dose of cabozantinib when administered alongside standard peptide receptor radionuclide therapy (PRRT).
- Other names
- cabozantinib + Lu-177 DOTATATEcabozantinib + Lutathera
02
Targets
AXL (AXL receptor tyrosine kinase)MET (Mesenchymal-epithelial transition factor receptor)SSTR2 (Somatostatin receptor type 2)VEGFR2 (Vascular endothelial growth factor receptor 2)DNA
Beyond the preview
Go deeper on cabozantinib + lutetium Lu 177 dotatate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cabozantinib + lutetium Lu 177 dotatate.